Dr. Reddy’s Laboratories Ltd ADR (RDY)
Dr. Reddy’s Laboratories Ltd. ADR is a depositary receipt representing common stock of Dr. Reddy’s Laboratories Limited, an integrated pharmaceutical company listed on the NYSE. Through its subsidiaries, the issuer operates across North America, Europe, India, Russia, and other international markets. Its business is organized into Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Global Generics covers branded and generic finished dosages, prescription and over-the-counter products, and biologics. PSAI focuses on active pharmaceutical ingredients, intermediates, contract research services, and steroids. The Others segment includes work in oncology, inflammation, and differentiated formulations. The company’s product portfolio spans therapeutic areas such as gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, nephrology, vaccines, and pain management. Founded in 1984, Dr. Reddy’s Laboratories is headquartered in Hyderabad, India.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-RDY
|
$13.14
|
7.7% Upside
|
Fair
|
$13.33
|
9.3% Upside
|
Fair
|
Good
|
0.5%
|
October 23, 2026
|
29.5x
|
2.5x
|
2.9x
|
10.161 B
|
10.092 B
|
6.8%
|
72.0%
|
10.5
|
20.1%
|
64.4%
|
